Cipher Pharmaceuticals (CPH) investor relations material

Executive summary

• Second quarter 2026 results reflect a highly profitable specialty pharma platform with strong cash flows and shareholder returns, despite pressure on U.S. Natroba sales volumes.

• Canadian portfolio, led by Epuris, showed growth and market share gains, offsetting some U.S. weakness.

• Epuris sales grew 14% year-over-year to $4.1 million in Q2 2026 and 4% sequentially from Q1 2026.

• Letter of Intent with pan-Canadian Pharmaceutical Alliance expands public reimbursement for Epuris, expected to drive further market share growth in Canada.

• Business development remains a key focus, with active pursuit of product in-licensing, out-licensing, and strategic acquisitions.

Financial highlights

• Total net revenue for Q2 2026 was $12.1 million, down 10% year-over-year; six-month revenue was $24.6 million, down 3%.

• Natroba revenue for Q2 2026 was $6.3 million, down from $7.8 million in Q2 2025; Epuris revenue grew 14% to $4.1 million.

• Net income for Q2 2026 was $4 million ($0.15/diluted share), down from $5.9 million ($0.22/diluted share) in Q2 2025.

• Adjusted EBITDA for Q2 2026 was $6.8 million (57% margin), down from $7.6 million in Q2 2025; YTD adjusted EBITDA was $14.6 million (59% margin), up from $13.8 million.

• Gross margin for Q2 2026 was 80%, down from 81% in Q2 2025; YTD gross margin was 81%, up from 79% in prior year.

Outlook and guidance

• Expectation for U.S. business remains positive, with anticipated improvement as new Natroba strategies take effect.

• Expanded public reimbursement for Epuris in Canada is expected to drive further market share growth.

• Focus remains on growing Natroba’s U.S. market share, leveraging opportunity as Permethrin loses efficacy.

• Plans to in-license or acquire complementary products and pursue Health Canada approval for Natroba.

• Continued focus on business development, including in-licensing, acquisitions, and out-licensing, as key growth drivers.